ORKA
Oruka Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$92.51
+1.67%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -27.5%
- EBIT
- -27.9%
- EPS
- +45.5%
- Free cash flow
- -3.3%
- Operating cash flow
- -3.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -4.3%
Three-year CAGR
- Revenue
- —
- EBITDA
- -28.1%
- EBIT
- -38.5%
- Net income
- -25.9%
- EPS
- +53.7%
- Free cash flow
- -52.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026